

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
06 September 2024 (06.09.2024)



(10) International Publication Number
WO 2024/180499 A1

(51) International Patent Classification:

C07D 239/95 (2006.01) C07D 471/08 (2006.01)
C07D 401/12 (2006.01) C07D 471/18 (2006.01)
C07D 403/12 (2006.01) C07D 491/08 (2006.01)
C07D 405/12 (2006.01) C07D 491/10 (2006.01)
C07D 417/12 (2006.01) A61K 31/517 (2006.01)
C07D 471/04 (2006.01) A61P 9/04 (2006.01)

(21) International Application Number:

PCT/IB2024/051925

(22) International Filing Date:

28 February 2024 (28.02.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/487,756 01 March 2023 (01.03.2023) US
63/550,180 06 February 2024 (06.02.2024) US

(71) Applicant: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35,
4056 Basel (CH).

(72) Inventors: **ANGST, Daniela**; Novartis Pharma AG, Licht-
strasse 35, 4056 Basel (CH). **BOLDUC, Philippe**; 324 East
St., Weymouth, Massachusetts 02189 (US). **CARSON,**
Matthew; Novartis Institutes for BioMedical Research,
Inc., 250 Massachusetts Avenue, Cambridge, Massachu-
setts 02139 (US). **CHEUNG, Atwood**; Novartis Institutes
for BioMedical Research, Inc., 250 Massachusetts Ave-
nue, Cambridge, Massachusetts 02139 (US). **DARSIGNY,**
Veronique; Novartis Institutes for BioMedical Research,
Inc., 250 Massachusetts Avenue, Cambridge, Massachu-
setts 02139 (US). **GAO, Xiang**; Novartis Institutes for
BioMedical Research, Inc., 250 Massachusetts Avenue,
Cambridge, Massachusetts 02139 (US). **HORNAK, Vik-**
tor; 30 High Haith Rd, Arlington, Massachusetts 02476
(US). **JENDZA, Keith**; 2239 W Eastman St., Boise, Iowa
83702 (US). **KARKI, Rajesh**; Novartis Institutes for Bio-
Medical Research, Inc., 250 Massachusetts Avenue, Cam-
bridge, Massachusetts 02139 (US). **LAL, Ajay Kumar**;
Novartis Institutes for BioMedical Research, Inc., 250
Massachusetts Avenue, Cambridge, Massachusetts 02139
(US). **LIU, Gang**; Novartis Institutes for BioMedical Re-
search, Inc., 250 Massachusetts Avenue, Cambridge, Mass-


achusetts 02139 (US). **MAO, Justin Yik Ching**; Novar-
tis Institutes for BioMedical Research, Inc., 250 Massa-
chusetts Avenue, Cambridge, Massachusetts 02139 (US).
MCKENNA, Jeffrey M.; Novartis Pharma AG, Licht-
strasse 35, 4056 Basel (CH). **MEREDITH, Erik**; 3 Ju-
dith Road, Hudson, Massachusetts 01749 (US). **MOGI,**
Muneto; Novartis Institutes for BioMedical Research,
Inc., 250 Massachusetts Avenue, Cambridge, Massachu-
setts 02139 (US). **RAUNIYAR, Vivek**; Novartis Institutes
for BioMedical Research, Inc., 250 Massachusetts Avenue,
Cambridge, Massachusetts 02139 (US). **SU, Liansheng**;
Novartis Institutes for BioMedical Research, Inc., 250
Massachusetts Avenue, Cambridge, Massachusetts 02139
(US). **TICHKULE, Ritesh Bhanudasji**; Novartis Insti-
tutes for BioMedical Research, Inc., 250 Massachusetts
Avenue, Cambridge, Massachusetts 02139 (US). **WANG,**
Shuangxi; Novartis Institutes for BioMedical Research,
Inc., 250 Massachusetts Avenue, Cambridge, Massachu-
setts 02139 (US). **ZHANG, Chun**; Novartis Institutes for
BioMedical Research, Inc., 250 Massachusetts Avenue,
Cambridge, Massachusetts 02139 (US). **ZHAO, Liang**;
Novartis Institutes for BioMedical Research, Inc., 250
Massachusetts Avenue, Cambridge, Massachusetts 02139
(US). **ZHENG, Rui**; 31 Lexington Ave., Needham, Mass-
achusetts 02494 (US).

(74) Agent: **NOVARTIS AG**; Lichtstrasse 35, 4056 Basel
(CH).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,

(54) Title: HYDROQUINAZOLINE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER



(57) Abstract: The disclosure relates to a compound of Formula (I): or a pharmaceutically acceptable salt thereof wherein A, R^a to R^d, and R⁴ to R⁷, are as described herein, as well as compositions and methods of using such compounds.

WO 2024/180499 A1

[Continued on next page]

SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*